(NASDAQ: ITCI) Intra Cellular Therapies's forecast annual revenue growth rate of 36.36% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Intra Cellular Therapies's revenue in 2024 is $464,370,000.On average, 5 Wall Street analysts forecast ITCI's revenue for 2024 to be $63,710,845,348, with the lowest ITCI revenue forecast at $63,114,416,244, and the highest ITCI revenue forecast at $64,357,420,577. On average, 5 Wall Street analysts forecast ITCI's revenue for 2025 to be $85,705,632,758, with the lowest ITCI revenue forecast at $76,649,029,618, and the highest ITCI revenue forecast at $93,167,240,618.
In 2026, ITCI is forecast to generate $115,541,512,217 in revenue, with the lowest revenue forecast at $94,716,155,674 and the highest revenue forecast at $132,450,533,847.